Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare Inc.
Your view on PBH
Overview
What the company does, where it operates, and who runs it.
About Prestige Consumer Healthcare Inc.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- William C. P'Pool
- Headquarters
- 660 White Plains Road, Tarrytown, NY, US
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- William C. P'Pool
- Headquarters
- 660 White Plains Road, Tarrytown, NY, US
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief.
The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products.
It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018.
Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Prestige Consumer Healthcare Inc., and the rating behind it. PBH last traded at $48.15, 13.4× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Prestige Consumer Healthcare Inc.. Starting points for Prestige Consumer Healthcare Inc.: P/E 13.4, EPS $3.62, beta 0.34 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Prestige Consumer Healthcare Inc.. Prestige Consumer Healthcare Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Prestige Consumer Healthcare Inc.. Trailing twelve-month EPS for Prestige Consumer Healthcare Inc. stands at $3.62. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Prestige Consumer Healthcare Inc.. Prestige Consumer Healthcare Inc. has reported as a listed company since 2005. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Prestige Consumer Healthcare Inc. valued side by side against its closest peers. Prestige Consumer Healthcare Inc. is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Prestige Consumer Healthcare Inc., and how their positions are changing. At a $2.28B market value, institutional positions materially move Prestige Consumer Healthcare Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Prestige Consumer Healthcare Inc. executives and directors. Shares of Prestige Consumer Healthcare Inc. have traded between $58.50 and $90.04 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Prestige Consumer Healthcare Inc.. Prestige Consumer Healthcare Inc. is a $2.28B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Prestige Consumer Healthcare Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Prestige Consumer Healthcare Inc.. Coverage tracks Prestige Consumer Healthcare Inc. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.